drugset / Trial / NCT00718250
Lentivirus Transduced Acute Myeloid Leukaemia Blasts Expressing B7.1 (CD80) and IL-2
Phase 1
Unknown
24 enrolled
King's College Hospital NHS Trust
Department of Health · collabElimination of Leukaemia Fund · collabLeukemia Research Fund · collab
Non-randomizedFactorialOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and tolerability of an 'AML Cell Vaccine' in patients with poor prognosis acute myeloid leukaemia (AML).
Timeline
- Start
- 2008-05
- Primary completion
- 2011-05
- Completion
- 2012-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RFUSIN2-AML1 | Vaccine | — | — |